Neuroimaging Findings in Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
This study aimed to discuss the neuroimaging findings and indications, epidemiological data, laboratory values, and the relationship of these variables with mortality in patients with COVID-19.

Detailed Description
-----------------
COVID-19 can present as neurological symptoms such as anosmia, headache, taste perversion, dizziness, syncope, and altered state of consciousness. It has been reported in previous studies that thromboembolic ischemic and hemorrhagic strokes associated with COVID-19 have been observed in the early period. It has been suggested that conditions characterized by neurological sequelae, such as encephalitis and encephalopathy, ataxic seizures, Guillain-Barré syndrome (GBS), demyelinating diseases, and neuromuscular disorders may occur in the longer term.In the present study, the investigators aimed to reveal the findings of neuroimaging analyses performed in patients followed up with a diagnosis of COVID-19 who had neurological symptoms, discuss the relationship of these findings with laboratory and epidemiological data, and emphasize that CNS involvement in these patients should not be overlooked. In this study, 436 patients with COVID-19 who underwent at least one neuroimaging procedure during April 2020-December 2020 due to neurological symptoms and whose diagnosis was confirmed by reverse transcriptase-polymerase chain reaction test were included. Although computed tomography was predominantly used for imaging, magnetic resonance imaging was also used when necessary. The patients were grouped based on imaging findings, and statistical evaluations were made between the groups.

Official Title
-----------------
Correlation of Neuroimaging Findings With Clinical Presentation and Laboratory Data in Patients With COVID-19: A Single Center Study

Conditions
-----------------
Neuroimaging, COVID-19

Intervention / Treatment
-----------------
* Diagnostic Test: Neuroimaging Findings in Patients With COVID-19


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 RT-PCR positivity- older than 18 years old Exclusion Criteria: younger than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>The first group consisted of 46 patients whose neuroimaging findings demonstrated acute/subacute infarction, bleeding, encephalitis, and venous sinus thrombosis | Diagnostic Test: Neuroimaging Findings in Patients With COVID-19<br>* MR and BT Imaging<br>|
| Group 2<br>The 2nd group (N=390) was obtained by subtracting the 1st group from all cases. | Diagnostic Test: Neuroimaging Findings in Patients With COVID-19<br>* MR and BT Imaging<br>|
| Group 3<br>The third group (N = 189) consisted of patients of the first group and patients with chronic ischemic changes observed in neuroimaging | Diagnostic Test: Neuroimaging Findings in Patients With COVID-19<br>* MR and BT Imaging<br>|
| Group 4<br>The 4th group (N=247) was obtained by subtracting the 3rd group from all cases. | Diagnostic Test: Neuroimaging Findings in Patients With COVID-19<br>* MR and BT Imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of acute thromboembolism in COVID-19 patients undergoing neuroimaging | Acute thromboembolic events are common in COVID-19 subjects undergoing neuroimaging, potentially due to an increased procoagulant process. | Between April and December 2020 |